Thank you.
The 2005 plan had six priorities, as you've indicated, one of which was manufacturing capacity. The other five--and I won't list all of them--included things like research, a clinical trials capacity, community engagement, intellectual property issues, and industrial engagement. That may have been all six now--I've lost track. Those were on the list in the first plan.
When we embarked upon developing the new 2010 plan, we didn't quite wipe the slate clean, but we almost did, recognizing, as you said, that there had been many changes, mostly scientific, over the last few years, which would require an update to this living plan. If the science isn't going to change, where has all that money gone? So indeed the science really has advanced the field. There is a new momentum and a real sense of optimism amongst the scientific community and the funders that we've made real progress and we need to build on it.
Back in 2009 we started a very broad engagement and consultation with members of the scientific community and with community groups around the world, to hear their perspectives on what the priorities were going forward.